Moreover, intratumoral injection of recombinant lytC_22 into CRC tumours promotes anti-PD1 therapy resistance in vivo by inducing intratumoral ARG1+ and iNOS+ MDSCs, thereby causing exacerbated T cell suppression. This evidence concerns the gene ARG1 and neoplasm.